the endothelial-haemostatic factors was, however, related to homocyst(e)ine levels. Mid-term folate Background. Haemodialysis patients exhibit an excessive burden of atherothrombotic disease, which is not supplementation decreased plasma homocyst(e)ine levels significantly without achieving normal values. explained adequately by traditional risk factors. Hyperhomocyst(e)inaemia, a consistent finding in No significant change of endothelial-haemostatic markers was observed, however, despite the drop in uraemic patients, is now widely recognized as an independent risk factor for vascular disease. The aim plasma homocyst(e)ine.
atherothrombotic event was present in 47.6% of the Introduction haemodialysed patients, and radiographic evidence of vascular calcifications in 70%.
The incidence of cardiovascular disease is remarkably Hyperhomocyst(e)inaemia was found in all patients, increased in dialysis patients and accounts for the averaging 3.5-fold the upper limit of normal values major cause of death in this group of subjects. The (P<0.001), despite the lack of clinical and biological relative risk of mortality from ischaemic heart disease evidence of malnutrition. Fibrinogen, von Willebrand has been estimated as 22-fold higher in dialysis patients factor and plasminogen activator inhibitor type 1, but than in the background population, a risk similar to not endothelin 1, were significantly higher in haemodiathat of survivors from a first myocardial infarction lysis patients than in controls. After adjustment for all (placebo arm of ISIS-2) [1] . This high cardiovascular variables, past history of cardiovascular events was morbidity and mortality in chronic haemodialysed independently associated with higher levels of homocypatients has led to the hypothesis of 'accelerated athst(e)inaemia only (odds ratio (OR) 1.06; 95% confiderosclerosis' since the excess burden of atherothromence interval (CI ) 1.01-1.12; P<0.026). The presence botic cardiovascular disease is not explained adequately of aortic calcifications was independently and significby the traditional cardiovascular risk factors including antly associated with age (OR 1.37; 95% CI 1.07-1.75; hypertension, diabetes, smoking and disorders of lipid P<0.025), homocyst(e)inaemia (OR 1.14; 95% CI metabolism, often present in these patients. 1.02-1.27; P<0.05) and fibrinogen concentration only Arterial lesions in uraemia consist of typical athero-(OR 9.74; 95% CI 1.25-75.2; P<0.05). None of sclerosis in a large percentage of dialysis patients studied before renal transplantation [2] . These atheroCorrespondence and offprint requests to: Professor T. Hannedouche, sclerotic lesions can be associated, although not con-calcifications located in the tunica media or internal supplementation, a manoeuvre known to lower plasma homocyst(e)ine [12] . elastic lamina without foam cells or macrophages [3] . Atherosclerosis is initiated through endothelial abnormalities [4] and elevated plasma concentrations of fibrinogen and of putative markers of endothelial dys-Subjects and methods function including von Willebrand factor (vWF ), tissue plasminogen activator (t-PA) and plasminogen Subjects activator inhibitor type 1 (PAI-1). All of these have
The study was conducted after approval of the local Ethics been shown to predict the risk of cardiovascular events Committee was obtained and after patients had given their [5, 6 ] , especially coronary accidents.
informed consent. The overall population of stable chronic Homocysteine is a sulfur-containing amino acid that haemodialysis patients in a single centre was investigated results from the demethylation of methionine. Patients after careful exclusion of patients under treatment with antiwith homocystinuria, a rare inherited metabolic defect epileptic drugs or other folate antagonists or oestrogens, as (defective cystathionine-b-synthase) leading to extra-well as those patients having taken vitamin B 12 or folate ordinarily high blood homocyst(e)ine levels, develop supplementation over the past 12 months.
Sixty three Caucasian patients met the following criteria widespread and severe atherosclerosis and generally and were enrolled in the study. Patients were characterized die before the age of 20 years from cerebral and as follows: 44 men, 19 women; mean age 59±13 years, mean coronary occlusive accidents [7] . duration of dialysis treatment 45±40 months. All patients Recently, milder increases in homocyst(e)ine have were dialysed for 4 h three times a week with standard been recognized as an independent risk factor for bicarbonate buffer and heparin anticoagulation. Initial stroke and other cardiovascular diseases [8, 9] . More nephropathy was chronic glomerulonephritis (n=29), diathan 20 case-control and cross-sectional studies of betic nephropathy (n=9), polycystic kidney disease (n=6), >2000 subjects consistently have indicated that interstitial nephritis (n=6), vascular nephropathy (n=4) and others (n=9).
patients with cardiovascular diseases tend to have All patients (n=63), as well as 40 age-matched healthy higher blood levels of homocyst(e)ine than subjects volunteers, serving as controls, were evaluated for measurewithout disease. It is of interest to note that most such ment of the following variables: serum albumin, insulin-like patients have homocyst(e)ine levels within what is growth factor 1 (IGF-1), IGF-BP3, vitamin B 12
, serum and considered the normal range [10] . The direct causal intra-erythrocyte folate, homocyst(e)ine, oxalic acid, total role of homocyst(e)ine in these cardiovascular events and high-density lipoprotein (HDL) cholesterol, triglycerides, is suggested by reports of vascular lesions induced in lipoprotein (a) [Lp(a)], fibrinogen, vWF, PAI-1, endothelin 1 ( ET-1). Blood samples were drawn in the fasting state baboons infused with homocysteine for 3 months and before a dialysis session. Samples were drawn on ice, immediof the toxic effect of homocyst(e)ine on vascular endoately centrifuged and stored at −80°C before specific anathelium [7] .
lysis. Calcium×phosphorus product and intact parathyroid
Hyperhomocyst(e)inaemia can be acquired in hormone (iPTH ) were calculated as the average of monthly several conditions including cobalamin or folate and tri-monthly determinations, respectively, over the 12 deficiency, and uraemia, where the increase in homo-months preceding the study. cyst(e)ine is positively correlated to plasma creatinine Traditional vascular risk factors such as hypertension, diabetes and smoking habits were also evaluated. Patients and culminates in dialysis patients [11] . In a cohort of were considered as hypertensive when they were receiving uraemic patients not requiring dialysis, we previously treatment with at least one antihypertensive drugs, as diahave found higher homocyst(e)ine levels in patients betics when hyperglycaemic and requiring insulin treatment, with cardiovascular complications than in patients and as a smoker when currently smoking more than five without such complications [11] , suggesting that part cigarettes or equivalent per day. of the 'accelerated atherosclerosis' could result from Past history of cardiovascular events was evaluated from hyperhomocyst(e)inaemia. However, the specific role in-centre medical records of each uraemic patients.
Myocardial infarction was diagnosed if the symptoms met of high homocyst(e)ine levels in inducing endothelial the WHO criteria and they were associated with either dysfunction, atherosclerosis and cardiovascular mor- The aims of the present study were: (i) to determine dromes were diagnosed according to clinical symptoms and the prevalence and magnitude of hyperhomocyst(e)ina-typical electrocardiographic or angiographic changes [13] . emia in a large cohort of haemodialysis patients and Strokes were diagnosed on the basis of medical records to assess the potential role of nutritional or folate showing a neurological deficit of sudden or rapid onset that persisted for >24 h. Strokes, either ischaemic or haemordeficiencies; (ii) to establish in these patients the potenrhagic, were confirmed on abnormal CT scans, which were tial link between hyperhomocyst(e)inaemia, past hisavailable in all cases of clinical strokes. Aortic aneurysms tory of cardiovascular events and present markers of and renal artery stenoses were documented by CT scan atherosclerosis such as vascular calcinosis; and (iii) to and/or angiograms. Peripheral vascular disease was diaelucidate the link between hyperhomocyst(e)inaemia gnosed based on clinical history (claudication, rest pain of and endothelial-haemostatic dysfunction.
the extremities, arterial bypass surgery or amputation) and This was evaluated by measuring plasma markers characteristic angiographic abnormalities.
Aortic calcinosis was assessed by radiographic detection of endothelial function before and after folate of calcified deposits in the abdominal aorta [14] . Lateral (e)ine concentrations were distributed normally in controls and the haemodialysis population, non-parametric abdominal films ( T12-S1) were made from a fixed distance with the subject seated. Calcifications in the abdominal aorta Wilcoxon's test was used for respective comparisons of controls vs patients; and patients with vs without cardiovaswere identified as linear densities in an area parallel and anterior to the lumbar spine (L1-L4) and were scored cular history or vascular calcifications. Fisher's exact test was used for the comparison of percentages between the two according to the length of the involved area. Nil calcification or <2 cm patchy calcifications were classified as absent, groups. A logistic regression model was used to assess the influence of all variables to determine past cardiovascular whereas larger streaks of calcification longer than 2 cm, generally found on both the anterior and posterior wall of events on the one hand and present vascular calcinosis on the other. Analysis of variance for repeated measurements the aorta, were considered as present. X-rays of the hand were performed and examined to confirm the absence or was used to compare the variation of blood pressure, renin, cGMP and NOx after captopril stimulation [18] . presence of calcinosis on small digital arteries.
To assess further the relationship between homocyst(e)inaStatistics were performed using the software SuperAnova@ (Abacus Inc., Berkeley, CA), and for the logistic regression emia, lipids and haemostasis-endothelial markers including fibrinogen, vWF, PAI-1 and ET-1, all these variables were analysis, SOLO version 4 (by BMDP Statistical Software Inc., Los Angeles, CA). determined before and after folate supplementation for 2 months, a manoeuvre reported to lower homocyst(e)ine levels in this group of patients [12] .
Patients were randomized into two groups treated either Results by placebo or by folic acid 10 mg administrated orally for a period of 8 weeks. After 8 weeks, homocyst(e)ine levels, Homocyst(e)ine and nutritional status endothelial markers, lipids and haemostatic factors were again determined.
Plasma homocyst(e)ine was significantly higher in diaIn addition, 10 patients of each group were chosen ran-lysis patients than in controls (44±24 vs 9±1.8 mmol/l; domly to study the effect on endothelial activation of lowering P<0.001, Figure 1 ); all patients had values exceeding homocyst(e)inaemia. To do so, we used the property of an the upper limit of the normal range (mean+2 SD= angiotensin-converting enzyme (ACE) inhibitor that, besides 13 mmol/l ) ( Table 1 ). This increase was not related to blocking generation of angiotensin II, also shows the catabolage, gender or haemodialysis duration, nor to any of ism of active bradykinin, a potent vasodilator acting through binding to an endothelial B2 receptor and stimulation of nitric oxide (NO) synthase. One hour before the start of the dialysis session, we determined blood pressure (oscillometric automatic device), plasma active renin concentration, plasma cGMP and plasma NO 2 -NO 3 (NOx), serving as putative terminal metabolites of NO), before (T0) and 30 min after (T30) the intake of a single oral dose of 25 mg of captopril.
Measurements
Plasma total homocyst(e)ine was determined by highperformance liquid chromatography coupled with a fluorometric detection method [15] . For the quantitative determination of folates in plasma and red blood cells (after haemolysis), we used the CIBA-Corning automated Chemiluminescence System (ACS ). IGF-1 and IGF-BP 3 were determined by competitive radioimmunoassay (RIA) (Nichols Institute, San Juan Capistrano, CA). ET-1 was quantified after acidification and extraction using RIA (Nichols Institute). Oxalic acid was measured by a colorimetric enzymatic assay. Albumin was determined by a colorimetric assay, cholesterol by an enzymatic assay, HDL cholesterol and Lp(a) by a nephelometric assay, and PAI-1 activity was measured by a chromogenic substrate assay (Biopool, Umea, Sweden). Fibrinogen determination was measured by the method of Clauss [16 ] . vWF was determined by a ristocetin agglutination technique. Active renin concentration was measured by the RENIN III kit (Institut Pasteur, Paris, France), cGMP was measured by RIA (Immunotech Int., Marseilles, France). Plasma nitrites and nitrates (NOx) were determined according to Green et al. [17] by a continuous flow method adapted on Alpkem analyser (ALPKEM Corp., Seattle, OR). otherwise. Although all variable and, specifically, homocyst- 
P<0.05).
Radiological evidence of aortic calcifications was present in 70% of patients (n=44), whereas small Homocyst(e)ine and cardiovascular complications vessel calcifications of the hands were found in 28% A history of cardiovascular atherothrombotic events (n=18), nearly all of the later patients having concomwas present in a substantial number of patients: occlus-itant aortic calcifications. ive arterial disease of the lower limbs 27% (n=17);
Both aorta and hand vessel calcifications were insigmyocardial infarction 16% (n=10); cerebrovascular nificantly more prevalent among patients with a history disease 11% (n=7); and abdominal aortic disease of cardiovascular events than in patients without such (aortic aneurysm+renovascular disease) 17% (n=11). complications ( Table 2) . By logistic regression, the Altogether, 47.6% of patients (n=30) had a history of presence of vascular calcifications (both hand vessels at least one vascular lesion. and aorta) was independently and significantly associAccording to the definition criteria, 17% of the ated with age (OR 1.16; 95% CI 1.001-1.34; P<0.05) patients were diabetic, 40% hypertensive and 25% and homocyst(e)inaemia only (OR 1.076; 95% CI smokers ( Table 2 ). The relationships among the pres-1.002-1.16; P<0.05). When considered separately, ence of cardiovascular events, traditional cardiovas-aortic calcifications, were independently and significcular risk factors, homocyst(e)ine and haemostatic antly associated with age (OR 1.37; 95% CI 1.07-1.75; factors are shown in Table 2 . Lp(a) was higher in P<0.025), homocyst(e)inaemia (OR 1.14; 95% CI patients than in controls, and above the upper limit of 1.02-1.27; P<0.05) and fibrinogen only (OR 9.74; normal (300 mg/l ) in 33% of the patients. Total choles-95% CI 1.25-75.2; P<0.05). Interestingly, vascular terol was similar, whereas HDL cholesterol was lower calcifications were not associated with serum iPTH, in patients than in controls. Total cholesterol was calcium×phosphate product and oxalaemia. >7 mmol/l in 10% of the patients. Fibrinogen and vWF concentrations were elevated in 95 and 62% of Haemostatic factors and endothelial markers the patients, respectively. The prevalence of these factors was, however, not different in patients with or Fibrinogen and vWF plasma concentrations and PAI-1 activity were significantly higher in haemodialysis without a history of cardiovascular complications. After adjustment for all putative variables (continuous patients than in controls, whereas ET-1 concentration was similar in patients and controls ( Table 1) . None and nominal given in Tables 1 and 2 ), past history of cardiovascular events was only independently associ-of the three variables (fibrinogen, vWF and PAI-1) was related to homocyst(e)ine levels. Unlike fibrinoated with higher levels of homocyst(e)inaemia with an odds ratio (OR) of 1.06 [95% confidence interval (CI ) gen, neither vWF nor PAI-1 was different in uraemic patients with or without cardiovascular history or plasma homocyst(e)ine, except for ET-1 which significantly decreased by 26% ( Table 3) . vascular calcinosis.
To study the influence of lowering homocyst(e)inaeThe 63 patients were included in a 2 month trial of mia on endothelial function, we have assessed, before folate supplementation. Of these, only 53 patients (25 and after the 8-week folate treatment, the acute treated; 28 controls) completed the study; two patients response of plasma cGMP and NOx to a challenge were transplanted, two died and six patients dropped with a single 25 mg dose of captopril ( Table 4 ). This out because of non-compliance. Folate administration was done in 10 patients, otherwise not treated by ACE of 10 mg a day, orally, was remarkably well tolerated inhibitors or angiotensin II receptor antagonists. The without any adverse effect. Plasma homocyst(e)ine acute increase in plasma cGMP suggested an endotheldecreased significantly in the folate-treated group ial response to captopril. However, the overall response (average decrease −23.4±38.4% in the folate-treated to captopril (decrease in blood pressure, increase in group vs +0.3±29.4% in the placebo group, active renin concentration, increase in plasma cGMP P<0.001), yet without returning to normal ( Table 3) . but not in NOx) was similar in nature and magnitude In only one out of 25 treated patients did the homocyst-before and after lowering hyperhomocyst(e)inaemia (e)ine level decreased to the normal range. There was ( Table 4) . a highly significant positive correlation between the decrease in total plasma homocyst(e)ine and the preDiscussion folate homocyst(e)ine level (r=0.945; P<0.0001), but not with the changes in plasma or erythrocyte folate. No significant change of endothelial markers or fib-Plasma homocyst(e)ine was significantly increased in all our haemodialysed patients. The mean level was rinogen was observed despite the marked variation in near 3-fold the upper limit of the normal values. Such the re-methylation in uraemic patients could be explained in terms of mass effect action and equilibrium high homocyst(e)ine levels consistently have been reported in small cohorts of uraemic patients before shift [21] .
Hyperhomocyst(e)inaemia is now recognized as an end-stage renal failure [11, 12] , or those treated by either haemodialysis [11, 19] or peritoneal dialysis independent risk factor for cardiovascular complications [10] . The main biological risk factors independ- [19, 20] . The mechanism of hyperhomocyst(e)inaemia in uraemic patients, however, remains elusive. ently associated with cardiovascular events in our cohort of haemodialysis patients were higher hyperhoHomocyst(e)ine accumulation in uraemia is not directly related to low glomerular filtration since renal mocyst(e)inaemia and calcium×phosphate product; this association persisted after adjustment for other excretion of homocysteine represents <0.1% of total production [21] . However, reduction in nephron mass 'traditional' risk factors. We previously have reported similar findings in a large series of uraemic patients could account for the accumulation of homocyst(e)ine. As for dibasic amino acids and cysteine, tubular cells not undergoing dialysis [11] .
High homocyst(e)ine levels can induce oxidation of play an important role in homocyst(e)ine metabolism through re-methylation and trans-sulfuration [21] .
low-density lipoprotein [23] and increase incorporation of Lp(a) into fibrin [24] . Lipid disorders are encounFolate or cobalamin deficiency is a major cause of acquired hyperhomocyst(e)inaemia [21] in the general tered frequently in uraemic patients. Among the different lipid fractions, an increased level of apoprotein B, population, where the concentration of homocyst(e)ine is negatively correlated with the intake and blood Lp(a), VLDL, chylomicrons, and a low level of HDL and apoprotein A-1 have been the best predictors of concentrations of folic acid, vitamin B 12 and vitamin B 6
[21]. Folate deficiency occasionally may occur in survival from cardiovascular diseases in uraemic patients [25] . In our study, Lp(a) was increased in malnourished dialysis patients [12] . Biological markers of malnutrition such as plasma IGF-1 and albumin one-third of all haemodialysis patients. There was no interaction between Lp(a), HDL cholesterol and were only minimally depressed in our cohort. In contrast, there was definitely no association of high homo-homocyst(e)ine levels. Interestingly the highest levels of Lp(a) were found in patients without vascular lesion, cyst(e)ine with low folate levels; both plasma levels and intracellular stores of folates were normal in our suggesting a 'survivor bias' effect [26 ] .
Aortic calcifications are predictive of cardiovascular patients. However, folate supplementation markedly reduced blood homocyst(e)ine levels in our uraemic mortality. Indeed, aortic abdominal calcifications detected on radiography were found to be associated patients, and the reduction was linearly related to pretreatment levels. Yet, homocyst(e)ine levels did not with a 6-fold higher risk of cardiovascular death in men aged 45 years independently of major cardiovasreturn to normal despite a huge increase in plasma and intracellular folate levels. Recently, massive cular risk factors [27] . Arterial calcification is composed of crystalline hydroxyapatite (Ca 10
2 ) intracellular accumulation of S-adenosylhomocysteine was demonstrated in uraemic patients; this potent and is closely linked to atherosclerosis in human arteries [28] . It has to be stressed, however, that mediacompetitive inhibitor of methyltransferase reactions could impair re-methylation as well as numerous cellu-calcinosis in dialysis patients is pathologically distinct from atherosclerotic lesions, which do not necessarily lar functions [22] . The folate-dependent stimulation of occur at the same time [3] . We found that the presence at the fibrin surface or on cell membranes is the basis of fibrinolysis. During the process, plasminogen is of calcifications of the small arteries or media-calcinosis of the aorta was associated essentially with patients' transformed into plasmin by t-PA, whose activity is regulated by its specific inhibitor, PAI-1. High levels age, hyperhomocyst(e)inaemia and, for aortic calcifications, high fibrinogen concentrations. It is of note of PAI-1 result in low fibrinolytic activity and correlate with serum insulin, obesity and hypertriglyceridaemia that, the arteriosclerotic lesions in children with homocystinuria due to defective cystathionine-b-synthase are [40] . High PAI-1 levels have been shown to predict the risk of recurrent myocardial infarction in younger mainly of the fibrous or fibrocalcific type [7] and are reminiscent of those observed in dialysis patients [3] .
non-uraemic men [41] and the occurrence of ischaemic accidents in atherosclerotic men [42] . Plasma PAI-1 Given experimental studies suggesting that hyperhomocyst(e)inaemia is responsible for endothelial lesions forms complexes with and inactivates plasma t-PA, hence high plasma antigen levels of t-PA reflect high [29] and can change haemostatic conditions from antithrombotic to thrombogenic [30-33], we were PAI-1 levels and low blood fibrinolytic activity [5] .
PAI-1 production can be stimulated by oxidized LDL interested in looking for a correlation between homocyst(e)inaemia and some putative biological markers of and cytokines such as TNF [43] , both of which are elevated in haemodialysed patients, but also depends endothelial-haemostatic dysfunction in vivo. Indeed, we found that fibrinogen, vWF and PAI-1 activity, but on a genetic polymorphism associated with myocardial infarction [44] . not ET-1, were elevated in our haemodialysis patients. The significant decrease in tHcy under folate Eight weeks of oral folate supplementation significantly decreased homocyst(e)inaemia, yet reaching supplementation was not associated with a similar reduction in plasma concentrations of markers of normal values in only one of 25 patients. Raising the question of the appropriate dose of folate, Bostom endothelial function, except for ET-1 which decreased significantly from initially normal values.
et al. have shown recently that supplementation with a multivitamin tablet containing 15 mg of folate, Fibrinogen is an inflammatory marker (hepatic acute phase reactant) as its synthesis is stimulated by cyto-100 mg of vitamin B 6 and 1 mg of vitamin B 12 could reduce tHcy to 15 mmol/l or less in one-third of dialysis kines, such as interleukin (IL)-1, IL-6 and tumour necrosis factor ( TNF ). Fibrinogen is also involved in patients having received 1 mg of folic acid daily previously [45] . Given the vast increase in plasma and intrablood coagulation and in the progression of atherothrombotic disease by participating in platelet erythrocytic folate levels obtained in our patients, it is unlikely that higher doses of folate, e.g. 15 mg per day, aggregation and in the formation of atheromatous plaques and parietal thrombi. Finally, fibrinogen is a could have led to a normalization of Hcy levels. Van Guldener et al. [46 ] did not find such a decrement major determinant of blood viscosity, an increase in which predisposes to thrombosis. Many recent studies after 15 mg of folate a day orally in their patients. On the other hand, Hong et al. found that 3 to 4-fold indicate that fibrinogen is a potent, discriminant, and an independent risk factor of cardiovascular events plasma folic acid concentrations did not suffice to reduce hyperhomocysteinaemia at all in dialysis [5, 6, 34] . The fibrinogen level was significantly increased in our haemodialysed patients, possibly due patients receiving a daily dose of 5 mg [47] .
We have not found any improvement of either the to the periodic cytokine-mediated inflammatory stimulation by the dialysis membrane, yet high fibrinogen endothelial-haemostatic markers or endotheliumdependent vascular reactivity, as evaluated by the levels have also been reported in uraemic non-dialysed patients [35] . In our study, high fibrinogen concentra-variations in serum cGMP and NO byproducts after stimulation by captopril. Our findings are in accordtion was found to be associated independently with the presence of aortic vascular calcinosis but not with ance with those of van Guldener et al. [46 ] , who also found no change in endothelial function parameters, the past occurrence of cardiovascular events. However, in our patients, high fibrinogen was not concordant neither biologically, nor by means of flow-mediated vasodilatation studies, nor after ultrasound vessel wall with hyperhomocyst(e)inaemia, in contrast to a previous report in non-renal patients with coronary artery analysis.
Based on epidemiological evidence [5, 6, 34, 39] , the disease and mildly elevated homocyst(e)ine and fibrinogen levels [36 ] . elevated levels of fibrinogen, vWF and PAI-1 activity theoretically could account for the high cardiovascular vWF is a glycoprotein originating from platelets, and even more from endothelial cells. It promotes morbidity and mortality observed in haemodialysis patients. However, and provided that measurement of platelet adhesion to damaged vessels and platelet aggregation in areas of high shear rates, thus contribut-plasma markers is sensitive enough to detect endothelial damage or haemostatic dysfunction, no firm funcing to thrombus formation. Increased levels of vWF in plasma are a marker of endothelial dysfunction or tional link between hyperhomocyst(e)inaemia and these markers could be demonstrated in the present injury and are predictive of recurrent myocardial infarction [36 ] . vWF was increased in our dialysis study.
In conclusion, haemodialysis patients exhibit a conpopulation, an observation also reported recently [35, 37, 38] .
stellation of biological disturbances known as cardiovascular risk factors in non-uraemic subjects. The PAI-1 is a 50 kDa protein synthesized and released by endothelial cells [39] . The activation of plasminogen association of these abnormalities could account for
